T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha
{"title":"478例阴茎鳞状细胞癌(pSCC)患者接受免疫检查点抑制剂(ICI)的真实结局","authors":"T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha","doi":"10.1136/jitc-2022-sitc2022.0478","DOIUrl":null,"url":null,"abstract":"Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI)\",\"authors\":\"T. Zhuang, S. Goyal, Jacqueline T. Brown, B. Carthon, Omer Kucuk, G. McClintock, L. Yantorni, M. Bilen, V. Master, B. Nazha\",\"doi\":\"10.1136/jitc-2022-sitc2022.0478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were\",\"PeriodicalId\":398566,\"journal\":{\"name\":\"Regular and Young Investigator Award Abstracts\",\"volume\":\"30 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regular and Young Investigator Award Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2022-sitc2022.0478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2022-sitc2022.0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI)
Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
